Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options
Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB...
Gespeichert in:
Veröffentlicht in: | Obstetrics and gynecology (New York. 1953) 2021-03, Vol.137 (3), p.454-460 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 460 |
---|---|
container_issue | 3 |
container_start_page | 454 |
container_title | Obstetrics and gynecology (New York. 1953) |
container_volume | 137 |
creator | Escobar, Christina M. Falk, Kerac N. Mehta, Shailja Hall, Evelyn F. Menhaji, Kimia Sappenfield, Elisabeth C. Brown, Oluwateniola E. Ringel, Nancy E. Chang, Olivia H. Tellechea, Laura M. Barnes, Hayley C. Jeney, Sarah E.S. Bennett, Alaina T. Cardenas-Trowers, Olivia O. |
description | Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB, are associated with cognitive side effects including dementia. β3-adrenoceptor agonists, the only alternative oral treatment for OAB, are similar in efficacy to anticholinergics with a more favorable side effect profile without the same cognitive effects. However, there are marked cost variations and barriers to access for OAB medications, resulting in expensive copays and medication trial requirements that ultimately limit access to β3-adrenoceptor agonists and more advanced procedural therapies. This contributes to and perpetuates health care inequality by burdening the patients with the least resources with a greater risk of dementia. When prescribing these medications, health care professionals are caught in a delicate balancing act between cost and patient safety. Through multilevel collaboration, we can help disrupt health care inequalities and provide better care for patients with OAB. |
doi_str_mv | 10.1097/AOG.0000000000004279 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2487150909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2487150909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4032-e493bf9f173fb01dbf92b10e2978c4c7f82cd9be27267e96a9a876c9e29330253</originalsourceid><addsrcrecordid>eNpdUdtOwkAQ3RiNIPoHxvTRl-Le6HYfkSiSkGAUE9-a7XYqlV5wd4Hw924FL3Fe5nbmzOQMQpcE9wmW4mY4G_fxH-NUyCPUJbFgIWXs9Rh1MaYyFDHnHXRm7bsHkUiyU9RhbMBZLEkXZU_gFkW9LOq34Bl0U2fhtKghmC_AqNUuyBsTzDY-1q7YQHBbqiwDE7gmmFQr0_jSo3IF1C4Yag3Wtp25AeWqtjZbuaKp7Tk6yVVp4eLge-jl_m4-egins_FkNJyGmmNGQ-CSpbnMiWB5iknmY5oSDFSKWHMt8pjqTKZABY0EyEhJFYtISw9gDNMB66HrPa-_7GMN1iVVYTWUpaqhWduE8liQAZZYeijfQ7VprDWQJytTVMrsEoKTVt_E65v819ePXR02rNMKsp-hb0F_ebdN6cDYZbnegkkWoEq3-OKL6ACHFFOCmc_C9imUfQKvZYVW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2487150909</pqid></control><display><type>article</type><title>Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options</title><source>Journals@Ovid Complete</source><creator>Escobar, Christina M. ; Falk, Kerac N. ; Mehta, Shailja ; Hall, Evelyn F. ; Menhaji, Kimia ; Sappenfield, Elisabeth C. ; Brown, Oluwateniola E. ; Ringel, Nancy E. ; Chang, Olivia H. ; Tellechea, Laura M. ; Barnes, Hayley C. ; Jeney, Sarah E.S. ; Bennett, Alaina T. ; Cardenas-Trowers, Olivia O.</creator><creatorcontrib>Escobar, Christina M. ; Falk, Kerac N. ; Mehta, Shailja ; Hall, Evelyn F. ; Menhaji, Kimia ; Sappenfield, Elisabeth C. ; Brown, Oluwateniola E. ; Ringel, Nancy E. ; Chang, Olivia H. ; Tellechea, Laura M. ; Barnes, Hayley C. ; Jeney, Sarah E.S. ; Bennett, Alaina T. ; Cardenas-Trowers, Olivia O.</creatorcontrib><description>Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB, are associated with cognitive side effects including dementia. β3-adrenoceptor agonists, the only alternative oral treatment for OAB, are similar in efficacy to anticholinergics with a more favorable side effect profile without the same cognitive effects. However, there are marked cost variations and barriers to access for OAB medications, resulting in expensive copays and medication trial requirements that ultimately limit access to β3-adrenoceptor agonists and more advanced procedural therapies. This contributes to and perpetuates health care inequality by burdening the patients with the least resources with a greater risk of dementia. When prescribing these medications, health care professionals are caught in a delicate balancing act between cost and patient safety. Through multilevel collaboration, we can help disrupt health care inequalities and provide better care for patients with OAB.</description><identifier>ISSN: 0029-7844</identifier><identifier>EISSN: 1873-233X</identifier><identifier>DOI: 10.1097/AOG.0000000000004279</identifier><identifier>PMID: 33543891</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><ispartof>Obstetrics and gynecology (New York. 1953), 2021-03, Vol.137 (3), p.454-460</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4032-e493bf9f173fb01dbf92b10e2978c4c7f82cd9be27267e96a9a876c9e29330253</citedby><cites>FETCH-LOGICAL-c4032-e493bf9f173fb01dbf92b10e2978c4c7f82cd9be27267e96a9a876c9e29330253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33543891$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Escobar, Christina M.</creatorcontrib><creatorcontrib>Falk, Kerac N.</creatorcontrib><creatorcontrib>Mehta, Shailja</creatorcontrib><creatorcontrib>Hall, Evelyn F.</creatorcontrib><creatorcontrib>Menhaji, Kimia</creatorcontrib><creatorcontrib>Sappenfield, Elisabeth C.</creatorcontrib><creatorcontrib>Brown, Oluwateniola E.</creatorcontrib><creatorcontrib>Ringel, Nancy E.</creatorcontrib><creatorcontrib>Chang, Olivia H.</creatorcontrib><creatorcontrib>Tellechea, Laura M.</creatorcontrib><creatorcontrib>Barnes, Hayley C.</creatorcontrib><creatorcontrib>Jeney, Sarah E.S.</creatorcontrib><creatorcontrib>Bennett, Alaina T.</creatorcontrib><creatorcontrib>Cardenas-Trowers, Olivia O.</creatorcontrib><title>Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options</title><title>Obstetrics and gynecology (New York. 1953)</title><addtitle>Obstet Gynecol</addtitle><description>Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB, are associated with cognitive side effects including dementia. β3-adrenoceptor agonists, the only alternative oral treatment for OAB, are similar in efficacy to anticholinergics with a more favorable side effect profile without the same cognitive effects. However, there are marked cost variations and barriers to access for OAB medications, resulting in expensive copays and medication trial requirements that ultimately limit access to β3-adrenoceptor agonists and more advanced procedural therapies. This contributes to and perpetuates health care inequality by burdening the patients with the least resources with a greater risk of dementia. When prescribing these medications, health care professionals are caught in a delicate balancing act between cost and patient safety. Through multilevel collaboration, we can help disrupt health care inequalities and provide better care for patients with OAB.</description><issn>0029-7844</issn><issn>1873-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdUdtOwkAQ3RiNIPoHxvTRl-Le6HYfkSiSkGAUE9-a7XYqlV5wd4Hw924FL3Fe5nbmzOQMQpcE9wmW4mY4G_fxH-NUyCPUJbFgIWXs9Rh1MaYyFDHnHXRm7bsHkUiyU9RhbMBZLEkXZU_gFkW9LOq34Bl0U2fhtKghmC_AqNUuyBsTzDY-1q7YQHBbqiwDE7gmmFQr0_jSo3IF1C4Yag3Wtp25AeWqtjZbuaKp7Tk6yVVp4eLge-jl_m4-egins_FkNJyGmmNGQ-CSpbnMiWB5iknmY5oSDFSKWHMt8pjqTKZABY0EyEhJFYtISw9gDNMB66HrPa-_7GMN1iVVYTWUpaqhWduE8liQAZZYeijfQ7VprDWQJytTVMrsEoKTVt_E65v819ePXR02rNMKsp-hb0F_ebdN6cDYZbnegkkWoEq3-OKL6ACHFFOCmc_C9imUfQKvZYVW</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Escobar, Christina M.</creator><creator>Falk, Kerac N.</creator><creator>Mehta, Shailja</creator><creator>Hall, Evelyn F.</creator><creator>Menhaji, Kimia</creator><creator>Sappenfield, Elisabeth C.</creator><creator>Brown, Oluwateniola E.</creator><creator>Ringel, Nancy E.</creator><creator>Chang, Olivia H.</creator><creator>Tellechea, Laura M.</creator><creator>Barnes, Hayley C.</creator><creator>Jeney, Sarah E.S.</creator><creator>Bennett, Alaina T.</creator><creator>Cardenas-Trowers, Olivia O.</creator><general>Lippincott Williams & Wilkins</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210301</creationdate><title>Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options</title><author>Escobar, Christina M. ; Falk, Kerac N. ; Mehta, Shailja ; Hall, Evelyn F. ; Menhaji, Kimia ; Sappenfield, Elisabeth C. ; Brown, Oluwateniola E. ; Ringel, Nancy E. ; Chang, Olivia H. ; Tellechea, Laura M. ; Barnes, Hayley C. ; Jeney, Sarah E.S. ; Bennett, Alaina T. ; Cardenas-Trowers, Olivia O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4032-e493bf9f173fb01dbf92b10e2978c4c7f82cd9be27267e96a9a876c9e29330253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Escobar, Christina M.</creatorcontrib><creatorcontrib>Falk, Kerac N.</creatorcontrib><creatorcontrib>Mehta, Shailja</creatorcontrib><creatorcontrib>Hall, Evelyn F.</creatorcontrib><creatorcontrib>Menhaji, Kimia</creatorcontrib><creatorcontrib>Sappenfield, Elisabeth C.</creatorcontrib><creatorcontrib>Brown, Oluwateniola E.</creatorcontrib><creatorcontrib>Ringel, Nancy E.</creatorcontrib><creatorcontrib>Chang, Olivia H.</creatorcontrib><creatorcontrib>Tellechea, Laura M.</creatorcontrib><creatorcontrib>Barnes, Hayley C.</creatorcontrib><creatorcontrib>Jeney, Sarah E.S.</creatorcontrib><creatorcontrib>Bennett, Alaina T.</creatorcontrib><creatorcontrib>Cardenas-Trowers, Olivia O.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Escobar, Christina M.</au><au>Falk, Kerac N.</au><au>Mehta, Shailja</au><au>Hall, Evelyn F.</au><au>Menhaji, Kimia</au><au>Sappenfield, Elisabeth C.</au><au>Brown, Oluwateniola E.</au><au>Ringel, Nancy E.</au><au>Chang, Olivia H.</au><au>Tellechea, Laura M.</au><au>Barnes, Hayley C.</au><au>Jeney, Sarah E.S.</au><au>Bennett, Alaina T.</au><au>Cardenas-Trowers, Olivia O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options</atitle><jtitle>Obstetrics and gynecology (New York. 1953)</jtitle><addtitle>Obstet Gynecol</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>137</volume><issue>3</issue><spage>454</spage><epage>460</epage><pages>454-460</pages><issn>0029-7844</issn><eissn>1873-233X</eissn><abstract>Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB, are associated with cognitive side effects including dementia. β3-adrenoceptor agonists, the only alternative oral treatment for OAB, are similar in efficacy to anticholinergics with a more favorable side effect profile without the same cognitive effects. However, there are marked cost variations and barriers to access for OAB medications, resulting in expensive copays and medication trial requirements that ultimately limit access to β3-adrenoceptor agonists and more advanced procedural therapies. This contributes to and perpetuates health care inequality by burdening the patients with the least resources with a greater risk of dementia. When prescribing these medications, health care professionals are caught in a delicate balancing act between cost and patient safety. Through multilevel collaboration, we can help disrupt health care inequalities and provide better care for patients with OAB.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>33543891</pmid><doi>10.1097/AOG.0000000000004279</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0029-7844 |
ispartof | Obstetrics and gynecology (New York. 1953), 2021-03, Vol.137 (3), p.454-460 |
issn | 0029-7844 1873-233X |
language | eng |
recordid | cdi_proquest_miscellaneous_2487150909 |
source | Journals@Ovid Complete |
title | Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T08%3A53%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rethinking%20Second-Line%20Therapy%20for%20Overactive%20Bladder%20to%20Improve%20Patient%20Access%20to%20Treatment%20Options&rft.jtitle=Obstetrics%20and%20gynecology%20(New%20York.%201953)&rft.au=Escobar,%20Christina%20M.&rft.date=2021-03-01&rft.volume=137&rft.issue=3&rft.spage=454&rft.epage=460&rft.pages=454-460&rft.issn=0029-7844&rft.eissn=1873-233X&rft_id=info:doi/10.1097/AOG.0000000000004279&rft_dat=%3Cproquest_cross%3E2487150909%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2487150909&rft_id=info:pmid/33543891&rfr_iscdi=true |